Ars Pharmaceuticals Inc (SPRY) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Ars Pharmaceuticals Inc   (NASDAQ: SPRY)

Select the Financial Report: Select the Period:


Description of Ars Pharmaceuticals Inc's Business Segments


Ars Pharmaceuticals Inc Overview

Ars Pharmaceuticals Inc is a forward-thinking pharmaceutical company dedicated to the treatment of respiratory diseases. The company is distinguished by its commitment to innovation in drug delivery systems and holistic patient support. Below is an extensive overview of its segments, products, and services.

Segments

1. Research & Development (R&D)
- The R&D segment at Ars Pharmaceuticals is pivotal to the companys mission. This team specializes in the exploration of novel compounds and formulations through preclinical and clinical research. The R&D efforts are directed toward not just developing new therapies but also optimizing existing products for better efficacy and safety. Clinical trials are conducted to ensure that new therapies meet regulatory standards and provide targeted relief for conditions such as asthma and chronic obstructive pulmonary disease (COPD). The researchers at Ars continuously monitor advancements in drug delivery technologies to stay at the forefront of respiratory care innovations.

2. Sales and Marketing
- The Sales and Marketing segment plays a crucial role in bringing Ars Pharmaceuticals products to market. This team works diligently to build relationships with healthcare providers, pharmacies, and hospitals to ensure broad access to its innovative products. They develop marketing strategies that educate healthcare professionals about the benefits and applications of the companys offerings. This segment also tracks market trends and conducts competitive analysis to adjust strategies accordingly, ensuring that the company remains relevant and responsive to the needs of the healthcare industry.

Products

1. AIRISTA
- AIRISTA is the flagship product of Ars Pharmaceuticals, regarded as a groundbreaking drug-device combination therapy. It is designed to deliver aerosolized medications directly to the lungs for patients suffering from respiratory diseases like asthma and COPD. AIRISTA utilizes advanced inhalation technology to enhance drug delivery efficiency, enabling patients to achieve better control of their conditions. This product stands out because it not only provides therapeutic benefits but also improves the overall patient experience through easier usage.

2. Other Respiratory Products
- In addition to AIRISTA, Ars Pharmaceuticals offers a comprehensive portfolio of pharmaceutical products aimed at treating respiratory diseases. This portfolio includes:
- Bronchodilators: Medications designed to relax and widen the air passages in the lungs, helping to alleviate symptoms of asthma and COPD.
- Anti-inflammatory Drugs: These medications help to reduce inflammation in the airways, providing relief from respiratory symptoms.
- Inhalers and Nebulizers: Devices designed for the effective delivery of medication to patients, ensuring that users receive the full therapeutic benefit of their prescriptions.

Services

1. Patient Education and Support
- Understanding that medication adherence and lifestyle management are crucial for patients with respiratory conditions, Ars Pharmaceuticals has developed comprehensive patient education programs. These programs provide supportive resources aimed at empowering patients through:
- Information on effective symptom management strategies.
- Guidelines for proper medication usage to maximize efficacy.
- Wellness initiatives addressing lifestyle factors that influence respiratory health.

2. Clinical Research
- The Clinical Research segment focuses on validating the safety and efficacy of Ars Pharmaceuticals products. This involves conducting rigorously designed clinical trials that are in line with FDA regulations and international standards. The research team works closely with regulatory bodies to ensure that its products not only meet safety standards but also provide meaningful clinical benefits to patients. Continuous research efforts also seek to innovate therapeutic options for future respiratory health.

3. Consulting and Education
- Ars Pharmaceuticals offers consulting and educational services aimed at healthcare professionals and institutions. This segment is committed to enhancing the understanding of respiratory diseases and their treatments through:
- Training programs for healthcare providers on the use and benefits of respiratory therapies.
- Dissemination of up-to-date research findings and treatment protocols.
- Collaborative initiatives to improve the overall quality of patient care in respiratory health.

Conclusion

Ars Pharmaceuticals Inc is dedicated to developing innovative solutions and products for the management of respiratory diseases. With a strong focus on research and development, extensive product offerings, and dedicated services aimed at patient support and healthcare education, the company’s efforts are geared towards improving the lives of individuals affected by respiratory conditions. This multifaceted approach ensures that Ars Pharmaceuticals remains a significant contributor to advancements in respiratory care.


Composition of Ars Pharmaceuticals Inc Revenues by Segments

 
Product    129.72 % of total Revenue
Denmark    10 % of total Revenue
Revenue under supply agreements    30.1 % of total Revenue
US    129.72 % of total Revenue
DK    17.14 % of total Revenue
Non Us    20.53 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Product 43.66 129.72 %
Denmark 3.37 10 %
Revenue under supply agreements 10.13 30.1 %
US 43.66 129.72 %
DK 5.77 17.14 %
Non Us 6.91 20.53 %
Total 33.66 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Product - -
Denmark - 21.17 %
Revenue under supply agreements 3036.53 % -
US - -
DK - -
Non Us - -
Total 114.15 % 48.4 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -62.34 -




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Ars Pharmaceuticals Inc Divisions, Sales by Country

 
United States   United States Segment contribution to total sales 85.66 % of total Revenue
Rest of World   Rest of World Segment contribution to total sales 14.34 % of total Revenue
A L K Collaboration Agreement ALK Financing Liability   A L K Collaboration Agreement ALK Financing Liability Segment contribution to total sales 0.24 % of total Revenue


Twelve months ended 2025
SPRY s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Total 84.28 100 %
United States 72.19 85.66 %
Rest of World 12.09 14.34 %
A L K Collaboration Agreement ALK Financing Liability 0.20 0.24 %


Twelve months ended 2025
SPRY s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -171.30 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Revenue under supply agreements - -
Total -5.46 % -
United States 895.07 % -
Rest of World -85.24 % -
Product revenue net - -
Revenue under collaboration agreements - -
ROW License - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.